Clinical Trial

M-2018-334 in Hematological Malignancies

Study acronym: HAPLO2022
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
This is a single-center, open-label, single-arm, pilot clinical study using TCRα/β and CD45RA depleted stem cell grafts from haploidentical donors for hematopoietic cell transplantation in 12 to 18 adult patients.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-01-15; most recent amendment 2025-11-25.
Trial Details
NCT Number NCT06225050
Lead Sponsor Miltenyi Biomedicine GmbH
Collaborators: City of Hope Medical Center
Conditions Hematological Malignancies
Enrollment 18 participants
Start Date 2026-02-28
Primary Completion 2029-02-28 (estimated)
Study Completion 2029-02-28 (estimated)
Updated on ClinicalTrials.gov 2025-12-03